Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.

about

Light Chain Amyloidosis.Novel Therapies in Light Chain Amyloidosis.

P2860

Q52659305-D47EF254-0BBF-40F6-900D-18132E7F91E1 Q55127439-0A5AB363-2D2C-439D-9CE4-441936E39E1D

P2860

Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.

Item

http://www.wikidata.org/entity/Q46463218

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Phase 2 trial of daily, oral e ...... with light-chain amyloidosis.

@en

Phase 2 trial of daily, oral e ...... with light-chain amyloidosis.

@nl

type

Item

label

Phase 2 trial of daily, oral e ...... with light-chain amyloidosis.

@en

Phase 2 trial of daily, oral e ...... with light-chain amyloidosis.

@nl

prefLabel

Phase 2 trial of daily, oral e ...... with light-chain amyloidosis.

@en

Phase 2 trial of daily, oral e ...... with light-chain amyloidosis.

@nl

P1476

Phase 2 trial of daily, oral e ...... with light-chain amyloidosis.

@en

P2093

Kenshi Suzuki

http://www.w3.org/2001/XMLSchema#string

Makoto Kobayashi

http://www.w3.org/2001/XMLSchema#string

Masatoshi Hotta

http://www.w3.org/2001/XMLSchema#string

Miku Goto

http://www.w3.org/2001/XMLSchema#string

Sohsuke Meshitsuka

http://www.w3.org/2001/XMLSchema#string

Yasuyo Wada

http://www.w3.org/2001/XMLSchema#string

Yuko M Sagesaka

http://www.w3.org/2001/XMLSchema#string

Yuuichi Ukawa

http://www.w3.org/2001/XMLSchema#string

P2860

Amyloid formation in light chain amyloidosis

A Single Mutation Promotes Amyloidogenicity through a Highly Promiscuous Dimer Interface

The crystal structure of the green tea polyphenol (-)-epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the thyroxine binding site

Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts.

Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway.

Mitochondrial respiratory chain dysfunction variably increases oxidant stress in Caenorhabditis elegans.

Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens.

A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction

P2888

s12185-016-2112-1

P304

295-308

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12185-016-2112-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Masanori Nojima

Sumito Shingaki

P577

2016-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27815860

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.

about

P2860

P2860

Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921